ANDREWS OFFICE PRODUCTS CAPITOL HEIGHTS, MD (K)

5

Assis de la companya della companya de la companya de la companya della companya

## KANEKA CASE REPORT FORM LDL-APHERESIS MA-01

Treatment	Date: 12 24 88	Number:	Location: Rogosin						
Patient I.D. Code: GKRA - 107									
	Manufacturer	Lot Number	Sterilization/Expiration						
SULFLUX:	Kaneka	710203080	87.07.12						
LA-15:	Kaneka	870606080-082	870606 -						
MEMBRANE FLT:	Kaneka	70612	870612						
LT-MA2 SET:	Kaneka	87123	87.07.12						
REGEN. FLUID:	Kaneka	AIA77	1989.7						
HEPARIN:	Lypho Med	338713A	3-30-80						
SALINE:	abbo #	24-927 FW	Jan 190						
RINGERS:	abbott	22-651-FW	Nov 1.90						
PATIENT INFORMATION  Patient Diagnosis: FH Homozygotes									
Access: Arterial Cutdown [ ] A/V Fistula [ ] Venous [ ]									
Othe		ko	•						
Age	Sex VM / F	Weight <u>26.3</u> is.	Heightft./in.						
Pre: Temp. (°C/°F) 37.5	Pulse 80 Re	B.P. BPM) <u>25</u> (mm/Hg) <u>110</u>	Plasma Vol. / 70 Estimated 2200 ml.						
Post: Temp. (°C/°F) 37.3	Pulse Re (BPM) 82 (E	esp. B.P. BPM) <u>23</u> (mm/Hg) <u>110 /</u>	Plasma Vol. 70 Actual 2200 ml.						
Time Blood Sa	mple is Drawn*	(hour:minute)	•						
Heparin Bolus	1200U+1500UIU Her	parin_ 250_IU/ml.	Flow Rate 1.5 ml./hr.						
*_ For	2700U	record the time the	nost treatment blood						

\*- For Rebound Studies, record the time the post treatment blood samples are drawn (Day 1 draw times must also be recorded).





130 MENS

THE ROGOSIN INSTITUTE
505 East 70 Street
New York, NY 10021

STUDY REGRESSION Atherosclerosis and LDL-Pheresis treatment regimen

## INDIVIDUAL PHERESIS DATA SHEET

1	_		_			TR EUFL	CESTS DA	ATA	SHE	<u>E'T'</u>			
Name:	Gilb	ert	Raz	zouk		חמ	:#: '#	1 i	07		D = 4	12	1 22 1 60
Visit #	:	6	1102	A	CCE		dle Arn	74	C+ >	<del></del>	Dat	:e: <u>                                   </u>	122/88
Rx#:		5'	1		raw		ure All	<u> </u>		rted		Ended	Length
	MA-01				<del></del>	irn 17	<del>-   }</del>			50		14:00	2.30
_		·	·			4111 //	10	<u> </u>	Pny	sici	an_		ırse
		.•								<del></del>		Whi	<u>te</u>
<u> </u>		·	<del></del>	-				•					
	WEIGH	IT	sysB	P	dy	sBP	PULSE	E	T	EMP	Н	EPARIN	J
	57.8	1			/4	L .	0.		6		┪ ¯		•
PRE	5/18	Ka	110			to	80		37	1. 8	1 13	5004	bolus
POST	28.2	2.2 cg 110		70		82		37.8			1200+ infuse		
CHANGE										·	1.50		n column
COLUMN	NO.												
TIME	NO.		50			1010					Т	otal	
	ESSED		.00		_	12:50							
RV	FOOFD			<del></del>	-							2200	
ACOAGUL	ANT	5	75			25		ļ	<del></del>				
PLASMA			0	<u> </u>		375		<b>├</b>					
RBC Total	P.C	<del> </del>	0	35		10 40	15	<del>├</del>					
INFUS.	PRESS.				+	70	50		<del></del>				
MA-OL-TUP		871	22	<u> </u>	_								
Plasma sed			0 B080			<del></del>		<del> </del>					
LA-15 Colum			06080	<del>''</del>				<b></b> _					
	2	2706	06082	<del></del>									
Membrane f	HER	700							·				
		<u>.                                    </u>								-		7, <del></del>	
ADVERSE (If Adve	REACT erse R	ION: eact	YES	NØ nd/or	CCI	U Malfı	CCU M	ALF	UNCI	NOI!	Y	es n	o atian
Sheet)				•				, -		Out	Auve	erse R	eaction
						· <u></u>	<del></del>	<del></del> -	<del></del>	<del></del>	<del>·</del>		
							<u> </u>	<del></del> -	<del>-</del>	<del></del>	<del></del>	<del></del>	
								· <del> , · -</del>	· · · · · · · · · · · · · · · · · · ·	·			
DID PATI	CENT C	OMPI	ETE PI	ROCEDU	RE	? (YES)	NO	(If	you	ans	were	ed "NO	", list
reason h	below)	٠,	,		•								
COMMENTS	i Fu	ast	June	(LQL	19	MA.	-01 c	LA	15	Lel	tes D	Today	Lack
-proced	leve	uel	<u>/</u>							7)			
<u> </u>	<del>-</del>	·····	,						<del></del>			·	
			<del></del>									·	
BLOODS I	י זגזע ג פֿר.												
PRE: Lipi										2			
1			••							·			
POST: 1-ip	. 1							<del></del> -	$\overline{\mathcal{I}}$	人			
-ib	1d5							-	<del>/ (/</del>	<del></del>		<del>}</del>	M.D.
'								/	[W)	lete	PN	<i>'</i>	R.N.
								/				<del></del>	